THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2020.
• Demonstrated that HEMO-CAR-T cells are effective against Acute Myloid Leukemia in vitro and in vivo • Developed a novel cell-based platform technology, referred to as CBR, for the treatment of emerging viral diseases, including COVID-19, as well as certain types of cancer
Hemogenyx Pharmaceuticals PLC Announces Final Results
LONDON, UK / ACCESSWIRE / April 30, 2021 / THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Final Results for the Year Ended 31 December 2020
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2020.
Key Highlights
in vitro and
in vivo
• Developed a novel cell-based platform technology, referred to as CBR, for the treatment of emerging viral diseases, including COVID-19, as well as certain types of cancer
Investegate |Hemogenyx Pharma Plc Announcements | Hemogenyx Pharma Plc: Conversion of Convertible Loan Notes investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
16 April 2021 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £950,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021. Pursuant to the conversion, the Company will issue, in aggregate, 24,547,803 new ordinary shares of £0.01 each in the capital of the Company (the New Ordinary Shares ) at a conversion price of £0.0387 per Ordinary Share.
Hemogenyx Pharmaceuticals PLC Announces Conversion of Convertible Loan Notes
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK / ACCESSWIRE / April 16, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has received a conversion notice from Mint Capital Advisors Ltd in respect of £950,000 in principal amount of the Convertible Loan Notes issued by the Company on 3 February 2021.
Pursuant to the conversion, the Company will issue, in aggregate, 24,547,803 new ordinary shares of £0.01 each in the capital of the Company (the New Ordinary Shares ) at a conversion price of £0.0387 per Ordinary Share.